Tolerance to WIN55,212-2 is delayed in desensitization-resistant S426A/S430A mice

Tolerance to cannabinoid agonists can develop through desensitization of the cannabinoid receptor 1 (CB1) following prolonged administration. Desensitization results from phosphorylation of CB1 by a G protein-coupled receptor kinase (GRK), and subsequent association of the receptor with arrestin. Mi...

Full description

Saved in:
Bibliographic Details
Published in:Neuropharmacology 2019-04, Vol.148, p.151-159
Main Authors: Nealon, Caitlin M., Henderson-Redmond, Angela N., Hale, David E., Morgan, Daniel J.
Format: Article
Language:English
Subjects:
Animals
Antinociception
Benzoxazines - pharmacology
Cannabinoid
CB1
Cyclohexanols - pharmacology
Desensitization
Dose-Response Relationship, Drug
Drug Tolerance
Hyperalgesia - chemically induced
Hyperalgesia - prevention & control
Hypothermia - chemically induced
Male
Mice
Morpholines - pharmacology
Mutation
Naphthalenes - pharmacology
Pain
Pain Measurement - drug effects
Receptor, Cannabinoid, CB1 - genetics
Time Factors
Tolerance
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tolerance to cannabinoid agonists can develop through desensitization of the cannabinoid receptor 1 (CB1) following prolonged administration. Desensitization results from phosphorylation of CB1 by a G protein-coupled receptor kinase (GRK), and subsequent association of the receptor with arrestin. Mice expressing a mutant form of CB1, in which the serine residues at two putative phosphorylation sites necessary for desensitization have been replaced by non-phosphorylatable alanines (S426A/S430A), display reduced tolerance to Δ9-tetrahydrocannabinol (Δ9-THC). Tolerance to the antinociceptive effects of WIN55,212-2 was delayed in S426A/S430A mutants using the tail-flick and formalin tests. However, tolerance to the antinociceptive effects of once daily CP55,940 injections was not significantly delayed in S426A/S430A mutant mice using either of these tests. Interestingly, the dose response curve shifts for the hypothermic and antinociceptive effects of CP55,940 that were induced by chronic treatment with this agonist in wild-type mice were blocked in S426A/S430A mutant mice. Assessment of mechanical allodynia in mice exhibiting chronic cisplatin-evoked neuropathic pain found that tolerance to the anti-allodynic effects WIN55,212-2 but not CP55,940 was delayed in S426A/S430A mice compared to wild-type littermates. Despite these deficits in tolerance, S426A/S430A mutant mice eventually developed tolerance to both WIN55,212-2 and CP55,940 for all pain assays that were examined, suggesting that other mechanisms likely contribute to tolerance for these cannabinoid agonists. These findings suggest that GRK- and βarrestin2-mediated desensitization of CB1 may strongly contribute to the rate of tolerance to the antinociceptive effects of WIN55,212-2, and raises the possibility of agonist-specific mechanisms of cannabinoid tolerance. •S426A/S430A mutation delays tolerance to WIN55,212-2.•GRK/β-arrestin-mediated CB1 desensitization facilitates tolerance to WIN55,212.•Tolerance to the hypothermic effects of CP55,940 is delayed in S426A/S430A mice.•S426A/S430A increased sensitivity to the antinociceptive effects of CP55,940.
ISSN:0028-3908
1873-7064
DOI:10.1016/j.neuropharm.2018.12.026